Chicago Capital LLC Cuts Stake in Zoetis Inc. $ZTS

Chicago Capital LLC cut its stake in shares of Zoetis Inc. (NYSE:ZTS) by 92.4% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 18,721 shares of the company’s stock after selling 226,129 shares during the quarter. Chicago Capital LLC’s holdings in Zoetis were worth $2,739,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the company. Scott & Selber Inc. grew its position in Zoetis by 0.6% during the 2nd quarter. Scott & Selber Inc. now owns 11,652 shares of the company’s stock valued at $1,817,000 after purchasing an additional 67 shares during the last quarter. North Star Asset Management Inc. grew its holdings in shares of Zoetis by 4.9% during the second quarter. North Star Asset Management Inc. now owns 1,441 shares of the company’s stock valued at $225,000 after buying an additional 67 shares during the last quarter. Secure Asset Management LLC increased its position in shares of Zoetis by 2.9% during the second quarter. Secure Asset Management LLC now owns 2,448 shares of the company’s stock valued at $382,000 after acquiring an additional 68 shares in the last quarter. Moment Partners LLC raised its holdings in Zoetis by 3.2% in the 2nd quarter. Moment Partners LLC now owns 2,354 shares of the company’s stock worth $367,000 after acquiring an additional 72 shares during the last quarter. Finally, CVA Family Office LLC lifted its position in Zoetis by 6.7% in the 2nd quarter. CVA Family Office LLC now owns 1,173 shares of the company’s stock valued at $183,000 after acquiring an additional 74 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

NYSE ZTS opened at $129.41 on Tuesday. The company has a 50-day moving average price of $124.66 and a 200-day moving average price of $141.33. Zoetis Inc. has a 52 week low of $115.25 and a 52 week high of $177.40. The company has a quick ratio of 2.28, a current ratio of 3.64 and a debt-to-equity ratio of 1.31. The firm has a market capitalization of $57.03 billion, a P/E ratio of 21.79, a PEG ratio of 2.57 and a beta of 0.97.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.08. Zoetis had a net margin of 28.21% and a return on equity of 57.19%. The company had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.42 billion. During the same period in the previous year, the business posted $1.58 earnings per share. The firm’s quarterly revenue was up .5% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities research analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 3rd. Stockholders of record on Tuesday, January 20th will be paid a $0.53 dividend. This is a positive change from Zoetis’s previous quarterly dividend of $0.50. The ex-dividend date is Tuesday, January 20th. This represents a $2.12 annualized dividend and a dividend yield of 1.6%. Zoetis’s dividend payout ratio (DPR) is currently 35.69%.

Analyst Ratings Changes

ZTS has been the subject of a number of research analyst reports. JPMorgan Chase & Co. reduced their target price on Zoetis from $230.00 to $200.00 and set an “overweight” rating for the company in a report on Wednesday, November 5th. KeyCorp started coverage on Zoetis in a report on Thursday, November 20th. They issued a “sector weight” rating for the company. Morgan Stanley set a $160.00 target price on Zoetis in a research report on Thursday, December 18th. BTIG Research reaffirmed a “buy” rating and set a $160.00 price target on shares of Zoetis in a report on Wednesday, December 3rd. Finally, Stifel Nicolaus reduced their price target on shares of Zoetis from $140.00 to $130.00 and set a “hold” rating for the company in a research note on Tuesday, November 18th. Six investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $160.18.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.